Y Intercept Hong Kong Ltd Sells 162,285 Shares of DENTSPLY SIRONA Inc. $XRAY

Y Intercept Hong Kong Ltd lessened its stake in shares of DENTSPLY SIRONA Inc. (NASDAQ:XRAY) by 90.6% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 16,798 shares of the medical instruments supplier’s stock after selling 162,285 shares during the quarter. Y Intercept Hong Kong Ltd’s holdings in DENTSPLY SIRONA were worth $195,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also made changes to their positions in the company. Daiwa Securities Group Inc. boosted its position in DENTSPLY SIRONA by 2.9% during the fourth quarter. Daiwa Securities Group Inc. now owns 26,814 shares of the medical instruments supplier’s stock valued at $306,000 after purchasing an additional 767 shares in the last quarter. Blue Trust Inc. lifted its position in shares of DENTSPLY SIRONA by 10.8% during the first quarter. Blue Trust Inc. now owns 12,555 shares of the medical instruments supplier’s stock valued at $146,000 after buying an additional 1,226 shares during the last quarter. Empowered Funds LLC boosted its holdings in shares of DENTSPLY SIRONA by 8.8% in the 1st quarter. Empowered Funds LLC now owns 16,324 shares of the medical instruments supplier’s stock valued at $244,000 after buying an additional 1,320 shares in the last quarter. Wilmington Savings Fund Society FSB boosted its holdings in shares of DENTSPLY SIRONA by 13.0% in the 4th quarter. Wilmington Savings Fund Society FSB now owns 13,055 shares of the medical instruments supplier’s stock valued at $149,000 after buying an additional 1,500 shares in the last quarter. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. purchased a new position in shares of DENTSPLY SIRONA in the 1st quarter worth approximately $26,000. 95.70% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of research firms recently commented on XRAY. Mizuho decreased their target price on shares of DENTSPLY SIRONA from $16.00 to $14.00 and set a “neutral” rating for the company in a research report on Wednesday, May 6th. UBS Group reduced their price target on DENTSPLY SIRONA from $18.00 to $17.00 and set a “buy” rating on the stock in a research report on Thursday, May 7th. Citigroup initiated coverage on DENTSPLY SIRONA in a research report on Wednesday, April 15th. They set a “sell” rating and a $10.00 target price on the stock. BMO Capital Markets initiated coverage on DENTSPLY SIRONA in a research note on Wednesday, July 8th. They issued a “market perform” rating and a $12.00 price target for the company. Finally, Weiss Ratings downgraded DENTSPLY SIRONA from a “sell (d-)” rating to a “sell (e+)” rating in a report on Wednesday, May 6th. Three analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and three have given a Sell rating to the stock. Based on data from MarketBeat.com, DENTSPLY SIRONA currently has an average rating of “Hold” and a consensus target price of $13.42.

DENTSPLY SIRONA Trading Up 5.6%

NASDAQ:XRAY opened at $13.41 on Thursday. The company has a market capitalization of $2.69 billion, a P/E ratio of -4.26, a PEG ratio of 1.51 and a beta of 0.89. The company has a current ratio of 1.53, a quick ratio of 0.98 and a debt-to-equity ratio of 1.52. DENTSPLY SIRONA Inc. has a 12 month low of $9.40 and a 12 month high of $17.09. The firm has a fifty day simple moving average of $10.70 and a 200-day simple moving average of $11.71.

DENTSPLY SIRONA (NASDAQ:XRAY) last released its earnings results on Tuesday, May 5th. The medical instruments supplier reported $0.27 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.28 by ($0.01). The firm had revenue of $880.00 million during the quarter, compared to analyst estimates of $841.80 million. DENTSPLY SIRONA had a negative net margin of 17.06% and a positive return on equity of 18.83%. DENTSPLY SIRONA’s revenue was up .1% on a year-over-year basis. During the same period in the previous year, the company earned $0.43 earnings per share. DENTSPLY SIRONA has set its FY 2026 guidance at 1.400-1.500 EPS. On average, equities research analysts anticipate that DENTSPLY SIRONA Inc. will post 1.42 earnings per share for the current year.

Insider Activity

In other news, Director Brian T. Gladden acquired 9,985 shares of the business’s stock in a transaction dated Monday, June 15th. The shares were acquired at an average cost of $10.02 per share, with a total value of $100,049.70. Following the completion of the acquisition, the director owned 61,849 shares of the company’s stock, valued at approximately $619,726.98. This trade represents a 19.25% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through this link. Also, Director Brian P. Mckeon acquired 10,000 shares of DENTSPLY SIRONA stock in a transaction dated Friday, June 12th. The stock was purchased at an average price of $10.12 per share, with a total value of $101,200.00. Following the completion of the purchase, the director owned 10,000 shares of the company’s stock, valued at approximately $101,200. The trade was a ∞ increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Over the last three months, insiders have bought 35,160 shares of company stock valued at $351,179. Company insiders own 0.46% of the company’s stock.

DENTSPLY SIRONA Profile

Dentsply Sirona Inc (NASDAQ: XRAY) is a leading global manufacturer of professional dental products and technologies. The company, formed through the merger of Dentsply International and Sirona Dental Systems in February 2016, brings together a long heritage of innovation in dental care. Headquartered in Charlotte, North Carolina, Dentsply Sirona develops and markets a comprehensive range of dental consumables, laboratory products, and advanced imaging and CAD/CAM systems.

The company’s product portfolio spans preventive, restorative, orthodontic, endodontic and surgical care.